Taken together, our findings support the potential of sEV proteins LAMB1 and Histone H4 in clinical applications and can provide valuable information for PCa detection, risk progression stratification, and best treatment strategy options. This evidence concerns the gene LAMB1 and posterior cortical atrophy.